Status:
COMPLETED
Mechanisms and Treatment of Intradialytic Hypertension
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Intradialytic Hypertension
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
1. To determine in a cross sectional case-controlled cohort study of 50 hemodialysis patients if blood pressure elevations with hemodialysis are associated with decreased endothelial cell function (me...
Eligibility Criteria
Inclusion
- on hemodialysis \> 30 days
- aged 18 to 80 years old
- ability to provide informed consent
- Primary nephrologist deems patient is at target dry weight
- Predialysis SBP \>140 or postdialysis SBP\>130
Exclusion
- Patients with active wounds
- Blood pressure unable to be measured by routine mechanisms in the upper extremity
- Change in blood pressure medications in the previous 2 weeks
- Intolerance of beta or alpha-blockers
- pregnancy
- Resting heart rate \<50
- Life expectancy \< 6 months
- Current therapy with carvedilol or contraindication to carvedilol (ONLY in the intervention arm)
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00827775
Start Date
June 1 2009
End Date
September 1 2010
Last Update
November 3 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
UTSW Oakcliff Davita Dialysis
Dallas, Texas, United States, 75224
2
UTSW Dallas East Davita Dialysis (Buckner unit)
Dallas, Texas, United States, 75228
3
UTS Dallas Dialysis (Elmbrook)
Dallas, Texas, United States, 75247